Noetik is a drug discovery company focused on developing precision cancer immunotherapies using AI. The Company has built an end-to-end platform, centered around proprietary generative AI models that identify novel representations of tumors. The Company has a unique process to generate hypotheses with AI (“in silico”) and test them in a scalable, repeatable fashion in living subjects (“in vivo”) generating a feedback loop to train and strengthen its models. Noetik uses the output from this process to identify new drug candidates.

Our other investment companies